Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?

Inclusion Criteria: * Both prevalent patients or patients newly started on continuous ambulatory peritoneal dialysis with age between 20 - 75 with or without diabetes mellitus will be considered eligible for study entry. For patients newly started on continuous ambulatory peritoneal dialysis, they will be suitable for recruitment into the study after one month on continuous ambulatory peritoneal dialysis. Exclusion Criteria: * Patients with underlying malignancy * Patients with chronic liver disease or liver cirrhosis * Patients with hepatitis B or C positive * Patients with active infections * Patients with other chronic active inflammatory disease such as systemic lupus erythematosus, rheumatoid arthritis * Patients who refuse study participation * Patients with underlying congenital heart disease or rheumatic heart disease * Patients with poor general condition * Patients with plans for living related kidney transplant within 2 years * Female patients with pregnancy * Patients with history of recurrent hypoglycemia * Patients with Class III and IV congestive heart failure * Patients already receiving glitazones treatment at the screening visit